Breast Cancer: Recurrent Genomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Kgeiersbach (talk | contribs) No edit summary |
Kgeiersbach (talk | contribs) No edit summary |
||
| Line 260: | Line 260: | ||
|''CBFB'' | |''CBFB'' | ||
|3 | |3 | ||
| | |Other/Complex | ||
|121360 | |121360 | ||
|CBFB | |CBFB | ||
| Line 1,456: | Line 1,456: | ||
|amplification | |amplification | ||
|Diseases: ER positive BC and luminal B; Therapy: BC cell lines overexpressing ZNF703 may be more resistant to tamoxifen treatment; Prognosis: may be poor in some cases (part of 8p11.2 gain/amplification) | |Diseases: ER positive BC and luminal B; Therapy: BC cell lines overexpressing ZNF703 may be more resistant to tamoxifen treatment; Prognosis: may be poor in some cases (part of 8p11.2 gain/amplification) | ||
|[https://pubmed.ncbi.nlm.nih.gov/21328542/ 21328542]; [https://pubmed.ncbi.nlm.nih.gov/21337521/ 21337521]; [https://pubmed.ncbi.nlm.nih.gov/23991038/ 23991038]; [https://pubmed.ncbi.nlm.nih.gov/24156016/ 24156016]; [https://pubmed.ncbi.nlm.nih.gov/33389351/ 33389351] | |[https://pubmed.ncbi.nlm.nih.gov/21328542/ 21328542]; [https://pubmed.ncbi.nlm.nih.gov/21337521/ 21337521]; [https://pubmed.ncbi.nlm.nih.gov/23991038/ 23991038]; [https://pubmed.ncbi.nlm.nih.gov/24156016/ 24156016]; [https://pubmed.ncbi.nlm.nih.gov/33389351/ 33389351] | ||
|} | |} | ||
Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. | Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. | ||